The Comparative Dosing and Glycemic Control of Intermediate and Long-Acting Insulins in Adult Patients With Type 1 and 2 Diabetes Mellitus.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY
Journal of Pharmacy Technology Pub Date : 2022-02-01 Epub Date: 2021-11-10 DOI:10.1177/87551225211055700
Anna Kabakov, Andrew Merker
{"title":"The Comparative Dosing and Glycemic Control of Intermediate and Long-Acting Insulins in Adult Patients With Type 1 and 2 Diabetes Mellitus.","authors":"Anna Kabakov,&nbsp;Andrew Merker","doi":"10.1177/87551225211055700","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The various basal insulin products possess differences in pharmacokinetics that can significantly impact glycemic control and total daily basal insulin dosing. In addition, there will be instances where transitions between the different long-acting insulins will need to be made. Because every basal insulin product is not interchangeable on a 1:1 unit-to-unit basis, it is important for health care providers to understand the expected dose adjustments necessary to maintain a similar level of glycemic control.</p><p><strong>Data sources: </strong>A Medline and Web of Science search was conducted in September 2021 using the following keywords and medical subjecting headings: NPH, glargine, detemir, type 1 diabetes mellitus, and type 2 diabetes mellitus.</p><p><strong>Study selection and data extraction: </strong>Included articles were those that followed adult patients with type 1 diabetes mellitus and/or type 2 diabetes mellitus and compared the following types of insulin: \"NPH and glargine,\" \"NPH and detemir,\" and \"glargine and detemir\" for at least 4 weeks, had documented basal insulin (BI) doses, and excluded pregnant patients.</p><p><strong>Data synthesis: </strong>Twenty-five articles were found that include adult type 1 and/or type 2 diabetes mellitus patients. Once daily NPH can be converted unit-to-unit to glargine or detemir. Twice daily NPH converted to glargine or detemir requires an initial 20% reduction in BI dose. An increase in dose of BI is recommended when transitioning from glargine to detemir. Glargine and detemir consistently resulted in improved glycemic control with lower incidence of hypoglycemic events compared with NPH.</p><p><strong>Conclusions: </strong>When transitioning between long-acting insulins, the doses are not always interchangeable on a 1:1 basis. Unit dose adjustments are likely if transitioning between BIs and can influence short-term parameters in the acute care setting and long-term parameters in the outpatient setting.</p>","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":" ","pages":"46-53"},"PeriodicalIF":1.1000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820046/pdf/10.1177_87551225211055700.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/87551225211055700","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/11/10 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The various basal insulin products possess differences in pharmacokinetics that can significantly impact glycemic control and total daily basal insulin dosing. In addition, there will be instances where transitions between the different long-acting insulins will need to be made. Because every basal insulin product is not interchangeable on a 1:1 unit-to-unit basis, it is important for health care providers to understand the expected dose adjustments necessary to maintain a similar level of glycemic control.

Data sources: A Medline and Web of Science search was conducted in September 2021 using the following keywords and medical subjecting headings: NPH, glargine, detemir, type 1 diabetes mellitus, and type 2 diabetes mellitus.

Study selection and data extraction: Included articles were those that followed adult patients with type 1 diabetes mellitus and/or type 2 diabetes mellitus and compared the following types of insulin: "NPH and glargine," "NPH and detemir," and "glargine and detemir" for at least 4 weeks, had documented basal insulin (BI) doses, and excluded pregnant patients.

Data synthesis: Twenty-five articles were found that include adult type 1 and/or type 2 diabetes mellitus patients. Once daily NPH can be converted unit-to-unit to glargine or detemir. Twice daily NPH converted to glargine or detemir requires an initial 20% reduction in BI dose. An increase in dose of BI is recommended when transitioning from glargine to detemir. Glargine and detemir consistently resulted in improved glycemic control with lower incidence of hypoglycemic events compared with NPH.

Conclusions: When transitioning between long-acting insulins, the doses are not always interchangeable on a 1:1 basis. Unit dose adjustments are likely if transitioning between BIs and can influence short-term parameters in the acute care setting and long-term parameters in the outpatient setting.

成人1型和2型糖尿病患者中、长效胰岛素的比较剂量和血糖控制。
目的:不同的基础胰岛素产品具有不同的药代动力学,可以显著影响血糖控制和每日基础胰岛素总剂量。此外,还需要在不同长效胰岛素之间进行转换。因为每一种基础胰岛素产品都不能以1:1的单位对单位进行互换,所以对医疗保健提供者来说,了解维持相似血糖控制水平所需的预期剂量调整是很重要的。数据来源:Medline和Web of Science检索于2021年9月进行,使用以下关键词和医学主题词:NPH、甘精、地替米尔、1型糖尿病和2型糖尿病。研究选择和数据提取:纳入的文章是那些跟踪1型糖尿病和/或2型糖尿病的成年患者,比较以下类型的胰岛素:“NPH和甘精”,“NPH和地特米”,“甘精和地特米”至少4周,有记录的基础胰岛素(BI)剂量,排除妊娠患者。资料综合:25篇文章纳入成人1型和/或2型糖尿病患者。一旦每日NPH可以单位到单位转换为甘精胺或迪特尔。每日两次的NPH转换为甘精氨酸或替特米尔需要初始BI剂量减少20%。当从甘精转换为替特尔时,建议增加BI剂量。与NPH相比,甘精氨酸和地替米持续改善血糖控制,降低低血糖事件发生率。结论:当在长效胰岛素之间转换时,剂量并不总是按1:1的基础互换。单位剂量调整是可能的,如果在BIs之间过渡,可以影响短期参数在急性护理设置和长期参数在门诊设置。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pharmacy Technology
Journal of Pharmacy Technology PHARMACOLOGY & PHARMACY-
CiteScore
1.50
自引率
0.00%
发文量
49
期刊介绍: For both pharmacists and technicians, jPT provides valuable information for those interested in the entire body of pharmacy practice. jPT covers new drugs, products, and equipment; therapeutic trends; organizational, legal, and educational activities; drug distribution and administration; and includes continuing education articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信